05-631 | Anti-IKKγ Antibody

05-631
100 µg  
Retrieving price...
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service

      Special Offers

       

      Contact Customer Service

      Click To Print This Page

      Overview

      Replacement Information

      Key Spec Table

      Species ReactivityKey ApplicationsHostFormatAntibody Type
      H, MWBMPurifiedMonoclonal Antibody
      Description
      Catalogue Number05-631
      Brand Family Upstate
      Trade Name
      • Upstate
      DescriptionAnti-IKKγ Antibody
      OverviewIKKγ/IKK3 is also known as NEMO, FIP-3 and IKKAP-1
      References
      Product Information
      FormatPurified
      PresentationPBS, pH 7.4, containing 0.02% sodium azide
      Applications
      ApplicationAnti-IKKγ Antibody is an antibody against IKKγ for use in WB.
      Key Applications
      • Western Blotting
      Biological Information
      ImmunogenHis-tagged, full-length human IKKgamma/IKK3
      HostMouse
      SpecificityIKKγ/IKK3
      IsotypeIgG
      Species Reactivity
      • Human
      • Mouse
      Antibody TypeMonoclonal Antibody
      Entrez Gene Number
      Entrez Gene SummaryFamilial incontinentia pigmenti (IP) is a genodermatosis that segregates as an X-linked dominant disorder and is usually lethal prenatally in males (The International Incontinentia Pigmenti Consortium, 2000 [PubMed 10839543]). In affected females it causes highly variable abnormalities of the skin, hair, nails, teeth, eyes, and central nervous system. The prominent skin signs occur in 4 classic cutaneous stages: perinatal inflammatory vesicles, verrucous patches, a distinctive pattern of hyperpigmentation, and dermal scarring. Cells expressing the mutated X chromosome are eliminated selectively around the time of birth, so females with IP exhibit extremely skewed X-inactivation. Familial incontinentia pigmenti is caused by mutations in the NEMO gene and is here referred to as IP2, or 'classical' incontinentia pigmenti. Sporadic incontinentia pigmenti, the so-called IP1, which maps to Xp11, is categorized as hypomelanosis of Ito (MIM 300337).[supplied by OMIM]
      Gene Symbol
      • IKBKG
      • FIP3
      • IPD2
      • NEMO
      • IP2
      • Fip3p
      • IP1
      • IKKG
      • IKK-gamma
      • AMCBX1
      • FIP-3
      • IKKAP1
      • IP
      Purification MethodProtein G Chromatography
      UniProt Number
      UniProt SummaryFUNCTION: SwissProt: Q9Y6K9 # Regulatory subunit part of the IKK-signalosome complex activation. Also considered to be a mediator for TAX activation of NF-kappa-B. Could be implicated in NF-kappa-B-mediated protection from cytokine toxicity.
      SIZE: 419 amino acids; 48198 Da
      SUBUNIT: Interacts preferentially with IKBKB/IKK-beta but also able to interact with CHUK/IKK-alpha, IKAP, RIP and MAP3K14/NIK. Found in a complex composed of NCOA2, NCOA3, CHUK/IKKA, IKBKB/IKKB and CREBBP. Interacts with COPS3, CYLD, NALP2, TRPC4AP and LRDD. Activated through binding to HTLV-1 Tax oncoprotein.
      SUBCELLULAR LOCATION: Cytoplasm. Nucleus.
      TISSUE SPECIFICITY: Heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas.
      DISEASE: SwissProt: Q9Y6K9 # Defects in IKBKG are the cause of X-linked anhidrotic ectodermal dysplasia with immunodeficiency (XL-EDA-ID) [MIM:300291]; also known as hypohidrotic ectodermal dysplasia with immunodeficiency (HED-ID). Ectodermal dysplasias (EDs) constitute a heterogeneous group of developmental disorders affecting tissues of ectodermal origin. EDs are characterized by abnormal development of two or more ectodermal structures such as hair, teeth, nails and sweat glands, with or without any additional clinical sign. Each combination of clinical features represents a different type of ectodermal dysplasia. XL-EDA-ID is characterized by absence of sweat glands, sparse scalp hair, rare conical teeth and immunological abnormalities resulting in severe infectious diseases. & Defects in IKBKG are the cause of anhidrotic ectodermal dysplasia with immunodeficiency, osteopetrosis and lymphedema (OL- EDA-ID) [MIM:300301]. & Defects in IKBKG are a cause of immunodeficiency without anhidrotic ectodermal dysplasia [MIM:300584]; also called isolated immunodeficiency or pure immunodeficiency. & Defects in IKBKG are the cause of susceptibility to X- linked familial atypical micobacteriosis type 1 (AMCBX1) [MIM:300636]; also known as X-linked disseminated atypical mycobacterial infection type 1 or X-linked susceptibility to mycobacterial disease type 1. AMCBX1 is the X-linked recessive form of mendelian susceptibility to mycobacterial disease (MSMD). MSMD is a congenital syndrome resulting in predisposition to clinical disease caused by weakly virulent mycobacterial species, such as bacillus Calmette-Guerin vaccines and non-tuberculous, environmental mycobacteria. Patients are also susceptible to the more virulent species Mycobacterium tuberculosis. & Defects in IKBKG are the cause of recurrent isolated invasive pneumococcal disease type 2 (IPD2) [MIM:300640]. Recurrent invasive pneumococcal disease (IPD) is defined as two episodes of IPD occurring at least 1 month apart, whether caused by the same or different serotypes or strains. Recurrent IPD occurs in at least 2% of patients in most series, making IPD the most important known risk factor for subsequent IPD. & Defects in IKBKG are the cause of familial incontinentia pigmenti type II (IP2) [MIM:308300]. IP2 is a X-linked dominant disease causing death in male fetuses. In heterozygous female, it is characterized by disturbance of skin pigmentation sometimes associated with a variety of malformations of the eye, nails, teeth, skeleton, heart, and central nervous system. The prominent skin signs occur in four classic cutaneous stages: perinatal inflammatory vesicles, verrucous patches, a distinctive pattern of hyperpigmentation and dermal scarring.
      Molecular Weight48kDa
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Quality Assuranceroutinely evaluated by immunoblot on RIPA lysates from Jurkat cells
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage Conditions2 years at -20°C
      Packaging Information
      Material Size100 µg
      Transport Information
      Supplemental Information
      Specifications

      Documentation

      SDS

      Title

      Safety Data Sheet (SDS) 

      Certificates of Analysis

      TitleLot Number
      Anti-IKKg/IKK3 (mouse monoclonal IgG1) - 2317770 2317770
      Anti-IKKg/IKK3 - DAM1394770 DAM1394770
      Anti-IKKg/IKK3 - DAM1690635 DAM1690635
      Anti-IKKg/IKK3 - DAM1794289 DAM1794289
      Anti-IKKgamma; - 22057 22057
      Anti-IKKgamma; - 23580 23580
      Anti-IKKgamma; - 24960 24960
      Anti-IKKγ/IKK3 -2596034 2596034
      Anti-IKKγ/IKK3 -2691208 2691208

      References

      Reference overviewApplicationPub Med ID
      Oncoprotein Suppression of Tumor Necrosis Factor-induced NF{kappa}B Activation Is Independent of Raf-controlled Pathways
      Hanson, J. L., et al
      J Biol Chem, 278:34910-34917 (2003)  2003

      Kinase Assay12851413 12851413

      Related Products & Applications

      Included Positive Control

      Catalogue Number Description  
      12-303 Jurkat Cell Lysate Show Pricing & Availability

      Categories

      Life Science Research > Antibodies and Assays > Primary Antibodies